Literature DB >> 8573730

Effects of a calcium channel blocker, manidipine, on insulin sensitivity in essential hypertensives.

O Iimura1, K Shimamoto, A Masuda, K Higashiura, Y Miyazaki, A Hirata, M Fukuoka, H Murakami.   

Abstract

This study was designed to investigate the effects of the calcium channel blocker manidipine on insulin-dependent glucose uptake (insulin sensitivity) and insulin action to renal sodium handling and pressor systems in essential hypertensive (EHT). Seven EHT were hospitalized and a 2-h euglycemic hyperinsulinemic glucose clamp was performed in a fasting condition before and after 2 weeks administration of manidipine (20 mg/day). Insulin sensitivity was evaluated as M-value calculated from the infusion rate of glucose. Manidipine administration decreased mean blood pressure and increased M-value significantly in EHT. Before the manidipine treatment, hyperinsulinemia during the clamp induced a decrease of urinary sodium excretion and increases of plasma norepinephrine and plasma renin activity in EHT. After manidipine treatment, however, hyperinsulinemia induced natriuresis and did not augment the pressor systems activity. Thus, the calcium channel blocker improved insulin resistance as assessed by glucose clamp technique in EHT. Suppression of augmented renal sodium reabsorption and pressor system activities of insulin may be connected with the hypotensive mechanisms and the natriuresis caused by calcium channel blockers.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8573730     DOI: 10.1016/1056-8727(95)80005-y

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  5 in total

Review 1.  Antihypertensive drugs and glucose metabolism.

Authors:  Christos V Rizos; Moses S Elisaf
Journal:  World J Cardiol       Date:  2014-07-26

Review 2.  Manidipine: a review of its use in hypertension.

Authors:  S M Cheer; K McClellan
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  Effects of manidipine and its combination with an ACE inhibitor on insulin sensitivity and metabolic, inflammatory and prothrombotic markers in hypertensive patients with metabolic syndrome: the MARCADOR study.

Authors:  Francisco J Martinez-Martin; Alicia Macias-Batista; Cristina Comi-Diaz; Herminia Rodriguez-Rosas; Paula Soriano-Perera; Pablo Pedrianes-Martin
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

Review 4.  Manidipine: a review of its use in the management of hypertension.

Authors:  Kate McKeage; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 5.  Manidipine-delapril combination in the management of hypertension.

Authors:  Manuel Luque Otero
Journal:  Vasc Health Risk Manag       Date:  2007
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.